Piper Sandler Upgrades Mesoblast to Overweight, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has upgraded Mesoblast (NASDAQ:MESO) from Neutral to Overweight and raised the price target from $4 to $11, indicating a positive outlook for the company's stock.
July 23, 2024 | 5:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Edward Tenthoff has upgraded Mesoblast from Neutral to Overweight and raised the price target from $4 to $11, suggesting a significant positive outlook for the stock.
The upgrade from Neutral to Overweight and the substantial increase in the price target from $4 to $11 by a reputable analyst at Piper Sandler indicates strong confidence in Mesoblast's future performance. This is likely to attract investor interest and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100